US FDA’s Non-Guidance On Osteoarthritis Drugs: Starting Over On Structural Claims

 
• By Michael McCaughan

Agency essentially ruling out use of structural endpoints to support disease progression claims for osteoarthritis drugs in new draft guidance.

More from Approval Standards

More from Pathways & Standards